search
lupus
Trends
- 1CAR T cell therapy shows two years free of lupus flares●Two years later, CAR T cell therapy shows promise for life without lupus flares
Researchers at UMass Chan Medical School report that lupus patients treated with CAR T cell therapy have remained free of disease flares two years after receiving the one-time cell-based treatment. The therapy, originally developed for blood cancers, reprograms a patient's own immune cells, and the latest follow-up data suggest it may offer lasting remission in autoimmune disease.
- 2Analysts Argue WILLOW Trial Endpoint, Not Enpatoran, Failed●The WILLOW Trial Didn’t Fail Enpatoran. The Endpoint Did.
Commentary around Merck KGaA's enpatoran is challenging the framing of the WILLOW trial results, arguing the drug was not proven ineffective but that the trial's chosen endpoint failed to capture the treatment effect. The piece says the outcome measure, not the therapy itself, is what fell short, reigniting debate over how lupus clinical trials are designed and judged.